Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

Walmart Inc. is giving $500,000 in grants and in-kind donations to Central Texas communities hit over the July Fourth weekend ...

WeightWatchers announces Dr. Kim Boyd as its new chief medical officer and unveils a program to support women through ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound. The company pledged ...

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Zepbound recorded nearly 339,000 prescriptions for the week ending April 18, overtaking Novo's obesity drug by more than 127,000. Lilly said it had captured about 53.3% of the U.S. market share.